Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Baudry

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
BMJ Open|October 10, 2025
PLAN-psoriasis: protocol for a randomised controlled feasibility trial comparing patient-led 'as-needed' treatment and therapeutic drug monitoring-guided treatment to continuous treatment for adults with clear or almost clear skin on risankizumab monotherapy for psoriasisWeiyu Ye, Kingsley Powell, Niamh Dooley, et al.
JAMA Dermatology|September 19, 2019
Association of Serum Ustekinumab Levels With Clinical Response in PsoriasisTeresa Tsakok, Nina Wilson, Nick Dand, et al.
Clinical and Translational Science|April 30, 2026
Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic StudyShan Pan, Teresa Tsakok, Ruoheng Wei, et al.
Clinical and Translational Science|January 30, 2020
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic StudyShan Pan, Teresa Tsakok, Nick Dand, et al.
The Journal of Allergy and Clinical Immunology|December 23, 2018
HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasisNick Dand, Michael Duckworth, David Baudry, et al.
The Journal of Investigative Dermatology|November 12, 2021
Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with PsoriasisKonstantinos Douroudis, Ravi Ramessur, Ines A Barbosa, et al.
JCI Insight|February 22, 2023
Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding grooveTeresa Tsakok, Jake Saklatvala, Theo Rispens, et al.
Biorxiv : the Preprint Server for Biology|April 3, 2026
Hidden immune memory niches in inflammatory skin diseasesLloyd Steele, April R Foster, Kenny Roberts, et al.
Genome Medicine|December 17, 2025
Genetic liability to psoriasis predicts severe disease outcomesJake R Saklatvala, Samuel Lessard, Maris Teder-Laving, et al.
Nature Communications|March 10, 2019
Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02Christos Tziotzios, Christos Petridis, Nick Dand, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
BMJ Open|October 10, 2025
PLAN-psoriasis: protocol for a randomised controlled feasibility trial comparing patient-led 'as-needed' treatment and therapeutic drug monitoring-guided treatment to continuous treatment for adults with clear or almost clear skin on risankizumab monotherapy for psoriasisWeiyu Ye, Kingsley Powell, Niamh Dooley, et al.
JAMA Dermatology|September 19, 2019
Association of Serum Ustekinumab Levels With Clinical Response in PsoriasisTeresa Tsakok, Nina Wilson, Nick Dand, et al.
Clinical and Translational Science|April 30, 2026
Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic StudyShan Pan, Teresa Tsakok, Ruoheng Wei, et al.
Clinical and Translational Science|January 30, 2020
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic StudyShan Pan, Teresa Tsakok, Nick Dand, et al.
The Journal of Allergy and Clinical Immunology|December 23, 2018
HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasisNick Dand, Michael Duckworth, David Baudry, et al.
The Journal of Investigative Dermatology|November 12, 2021
Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with PsoriasisKonstantinos Douroudis, Ravi Ramessur, Ines A Barbosa, et al.
JCI Insight|February 22, 2023
Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding grooveTeresa Tsakok, Jake Saklatvala, Theo Rispens, et al.
Biorxiv : the Preprint Server for Biology|April 3, 2026
Hidden immune memory niches in inflammatory skin diseasesLloyd Steele, April R Foster, Kenny Roberts, et al.
Genome Medicine|December 17, 2025
Genetic liability to psoriasis predicts severe disease outcomesJake R Saklatvala, Samuel Lessard, Maris Teder-Laving, et al.
Nature Communications|March 10, 2019
Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02Christos Tziotzios, Christos Petridis, Nick Dand, et al.
Pageof 3